426 results about "Nasopharyngeal carcinoma" patented technology

The present invention relates to a pentacyclic triterpanoid derivative of multiple-oxide substitution of the A ring and the C ring and the medicine salt or solvate of the derivative, and the present invention also relates to the preparation method, the drug combination, and medical use of the derivative. The compound of the present invention has the functions of inhibiting the activity of six human tumor cell strains in vitro, such as human prostate cancer cell (PC-3), nasopharyngeal carcinoma cells (CNE), oral squamous carcinoma cell(KB), human lung cancer cell (A549), human hepatoma cell (BEL-7404), and human cervix cancer cell (Hela), and the function of the invention is at the same magnitude of the positive control of cisplatin, thereby the compound can be used as expected antitumor drug. The compound of the present invention also inhibits the alpha glucosidase strongly, and the inhibiting effect is greater than the positive control of acarbose, thereby the compound can be used as expected medicine for preventing and treating diabetes and the treatment of the virus diseases.

The invention discloses a nasopharyngeal-carcinoma (NPC) lesion automatic-segmentation method and nasopharyngeal-carcinoma lesion automatic-segmentation systems based on deep learning. The method comprises: carrying out registration on a PET (Positron Emission Tomography) image and a CT (Computed Tomography) image of nasopharyngeal carcinoma to obtain a PET image and a CT image after registration;and inputting the PET image and the CT image after registration into a convolutional neural network to carry out feature representation and scores map reconstruction to obtain a nasopharyngeal-carcinoma lesion segmentation result graph. The method carries out registration on the PET image and the CT image of the nasopharyngeal carcinoma, obtains a nasopharyngeal-carcinoma lesion by automatic segmentation through the convolutional neural network, and is more objective and accurate as compared with manual segmentation manners of doctors; and the convolutional neural network in deep learning isadopted, consistency is better, feature learning ability is higher, the problems of dimension disasters, easy falling into a local optimum and the like are solved, lesion segmentation can be carried out on multi-modal images of the PET-CT images, and an application range is wider. The method can be widely applied to the field of medical image processing.

A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. Another application is heart preservation in situations where there is a lack of oxygen supply in vivo, such as in heart transplant or oxygen-deprived heart.

Apparatus and methods for withdrawing nasopharyngeal fluid samples from a patient are disclosed. A kit including a catheter and a manual suction device is disclosed, wherein the catheter can be self-navigating and define aspiration holes through which aspiration fluid can be emitted and nasopharyngeal fluid samples can be withdrawn. The catheter may also include an insertion depth scale to ensure patient comfort and optimum sample quality. The methods for obtaining nasopharyngeal fluid samples include the steps of inserting the catheter into a patient's nasopharynx, and aspirating the nasal pharynx to withdraw a specimen.

The invention provides a kit for detecting 7 genetic markers of peripheral blood in early diagnosis of nasopharyngeal darcinoma. The kit comprises a peripheral blood total RNA extracting reagent, RT-PCR reaction liquid, time fluorescence quantitative RT-PCR reaction liquid and an SVM nasopharyngeal darcinoma diagnosis model, wherein the time fluorescence quantitative RT-PCR reaction liquid comprises primers of which the sequences are shown as SEQ IDNO:1-16; the primer sequences are SYBR Green fluorescence quantitative RT-PCR detection primers of the 7 genetic markers and reference gene GAPD; and the 7 genetic markers are HERC5, DLG7, PPARG, PLK1, KIF15, KLHL25 and MYST4. The invention also provides a using method for the kit. The kit has the advantages of high sensitivity, specificity and convenience, and can be used as aided diagnosis and early diagnosis technology for the nasopharyngeal darcinoma.

The invention discloses an in situ hybridization probe, a reagent and an application of long non-coding RNA LOC401317. The long non-coding RNA LOC401317 can be used for preparing a prognosis preparation for a patient with nasopharyngeal carcinoma, and particularly a kit for predicting prognosis of the patient with the nasopharyngeal carcinoma employing an in situ hybridization detection method is prepared. A research proves that expression of the LOC401317 in a nasopharyngeal carcinoma tissue is lowered, and the patient with the nasopharyngeal carcinoma in low-expression LOC401317 is worse than the patient with the nasopharyngeal carcinoma in high-expression LOC401317 in prognosis, therefore, expression of the LOC401317 is applied to prognosis prediction of the patient with nasopharyngeal carcinoma; a powerful molecular biology basis can be provided for prognosis of the patient with the nasopharyngeal carcinoma; and the long non-coding RNA LOC401317 has profound clinical significance and important popularization and application prospects.

The invention belongs to the field of hospital information processing. A medical care information management system is used for performing medical information management on patients with nasopharyngeal carcinoma by medical care personnel, comprises a patient mobile terminal, a network data management platform system and a cloud server, and further comprises a medical care information management PCterminal, wherein the medical care information management PC terminal comprises a user right management module, a patient management module, a prompting module, an information distribution module anda circle module. The patient mobile terminal is used for collecting patient-related information and uploading the information to the network data management platform system; the medical care information management PC terminal is used for the medical care personnel to call and input the patient-related information from the network data management platform system; the network data management platform system is used for receiving, storing, analyzing and processing relevant data and transmitting the data to patient mobile terminal and the medical care information management PC terminal. The medical care information management system can provide medical care management service with high convenience and service performance for the medical care personnel.

A method for preparing EB viral protein enzyme-linked immunosorbent diagnostic kit includes selectng EBNAl (BKRF1) prote, Zta (BZLF1) protein and VCA-p18 protin in EB viral protein for diagnosing nasopharyngeal carcinoma of serodiagnosis as target antigen for detecting antibody level in blood serum, using glutathione-transferase gene fusion system to carry on clone, presentation and purification of EB viral protein for creating diagnostic kit.

The invention provides a nasopharyngeal carcinoma focus segmentation model training method and segmentation method based on deep learning, and the method comprises the following steps: I, loading a trained segmentation model into a convolutional neural network model; II, reading the nasopharyngeal carcinoma MRI original image; III, normalizing the nasopharyngeal carcinoma MRI original image to obtain a nasopharyngeal carcinoma MRI image; IV, inputting the nasopharyngeal carcinoma MRI image into the convolutional neural network model to obtain a focus probability map of the nasopharyngeal carcinoma MRI image; And V, binarizing the focus probability map of the nasopharyngeal carcinoma MRI image to obtain a focus segmentation map. The invention further provides a nasopharyngeal carcinoma focus segmentation model training method. The model obtained through the nasopharyngeal carcinoma focus segmentation model training method based on deep learning is applied to the focus segmentation method, and the problem of poor effect caused by small image segmentation in the nasopharyngeal carcinoma MRI image can be effectively solved, so that the segmentation effect of the target small image is improved, and the nasopharyngeal carcinoma focus is segmented more accurately and automatically.

The invention discloses a Chinese medicine for remedying lymphoma, nasopharyngeal carcinoma and brain tumor, and relates to the Chinese medicine field. The prior cancer remedying method of western medicine mainly adopts surgical operation, radiotherapy and chemotherapy methods, the curative effect of which is not ideal. The cancer remedying method of western medicine damages the healthy organisms to a certain extent. Chinese medicine cures the cancers dialectically, invigorates yang and restrains yin, and achieves the purpose of exterminating cancer cells. The Chinese medicine is made from a plurality of raw materials of field pennycress, sargentgloryvine stem, motherwort, flagleaf and so on. The raw materials are crushed and sieved by a 360 sieve. The ferruginous contents are removed by magnetization. After being sterilized, the crushed raw materials are filled in small bags. The Chinese medicine can be taken by decocting into decoction which can be taken separately or taken together with residues. The clinical trial proves that the invention has the beneficial effect that the Chinese medicine is quick to take effect, has high curative effect and simple preparation technology, is convenient to be popularized, has low cost, not only is favorable to the treatment of patients, but also is suitable for the illness prevention for healthy people.

The invention discloses application of a reagent for inhibiting circ_CLASP2 (Cytoplasmic Linker Associated Protein 2) in preparation of a preparation for treating nasopharyngeal darcinoma and the preparation. A research proves that the circ_CLASP2 is inhibited in nasopharyngeal darcinoma cells, and the proliferation, invasion and metastasis of the nasopharyngeal darcinoma cells can be inhibited. Therefore, a circ_CLASP2 inhibitor is used for treating the nasopharyngeal darcinoma and has profound clinical significance and an important popularization and application prospect.

The invention discloses a nasopharyngeal carcinoma primary lesion clinical target area automatic drawing method based on a mutual correlation rule. The method comprises a step of generating a binary image of a nasopharyngeal primary tumor area, a step of removing instable data of a tumor outermost layer, a step of carrying out data discretization operation on the image sequence of a template CT, and dividing the image sequence and generating corresponding three-dimensional grids, a step of counting the frequency that voxel combination appears, and establishing a database of a correlation rule, a step of reading new patient gross tumor data with the need of drawing a clinical target area, using the mutual correlation rule, simulating tumor growth, and automatically drawing a clinical radiotherapy target area. Compared with manual drawing at present, the automation of drawing is realized by the system, and the working efficiency of a doctor is improved. A drawing result reaches a drawing standard required by the doctor, and local adjustment is taken as post processing and is provided for the doctor for selection.

The invention relates to a new application of furanodiene in pharmacy field, in particular to the application of the furanodiene in the preparation of medicines for treating the various malignant tumor diseases such as oophoroma, cervical carcinoma, gastric cancer, liver cancer, leucocythemia, lung cancer, oral carcinoma (epidermoid carcinoma), rectal adenocarcinoma, mammary cancer, malignant melanoma, colonic adenocarcinoma, nasopharyngeal carcinoma, carcinoma of prostate, etc. The invention also relates to the application of the furanodiene in the preparation of drugs for treating the diseases caused by herpesvirus, influenza virus and hepatitis B virus.

The invention discloses an anti-tumor combination and the application thereof; the anti-tumor combination which includes effective dose of platinum-based chemotherapy and AKT inhibitor and / or p70S6K1 inhibitor has the function of inhibiting the drug resistance of the tumor to the platinum-based chemotherapy, improves the effects of anti-tumor drugs, and can be used for preparing drugs that can resist various tumors, such as lung cancer, ovarian cancer, prostate cancer, breast cancer, stomach cancer, nasopharyngeal cancer, esophageal cancer, malignant lymphoma, head and neck squamous cell carcinoma, thyroid cancer, osteosarcoma, etc.

The invention relates to a 2,3-dioxyethyl-5-methyl-8,9-dimethoxy benzophenanthridine derivative disclosed as Formula I, a synthesis method and application thereof in preparing medicines for inhibiting tumor cell activity. The 50% inhibition concentrations IC50 of the 2,3-dioxyethyl-5-methyl-8,9-dimethoxy benzophenanthridine-hydrochloride and hydrobromide for four cancer cell strains of stomach cancer (MGC-803), liver cancer (BEL7402), human nasopharyngeal carcinoma (CNE) and human lung adenocarcinoma (A549) are respectively lower than those of nitidine chloride, and are much lower than those of 5-FU (control drug).

The invention belongs to the technical field of cell biology, and more specifically relates to a sequence of an aptamer used for targeting human nasopharyngeal carcinoma cell and an application thereof. According to the invention, the aptamer capable of specifically combining with human nasopharyngeal carcinoma cells strain 5-8F is screened, so that a sequence S3 capable of specifically combining with 5-8F is obtained. The aptamer of nasopharyngeal carcinoma cell 5-8F has unique stem-loop structure under condition of 0 DEG C, 157mol/L Na<+>, and 0.005mol/L Mg<2+>. The sequence of the aptamer of nasopharyngeal carcinoma cell 5-8F has application prospect on preparation of a nasopharyngeal carcinoma diagnostic reagent, a nasopharyngeal carcinoma treatment medicine, and a nasopharyngeal carcinoma tumour marker, and research of variation of nasopharyngeal carcinoma and normal tissue, nasopharyngeal carcinoma tissue sectioned imaging, nasopharyngeal carcinoma-related in-vivo imaging and nasopharyngeal carcinoma targeting treatment.

UL16 binding protein 2 (ULBP2) is a protein overexpressed in pancreatic cancer tissues, and the ULBP2 levels are significantly higher in pancreatic cancer patients than those in healthy controls. This invention provides a method to detect pancreatic cancer using ULBP2 as a serological marker. The combination of ULBP2 and CA19-9 promotes the efficacy of pancreatic cancer detection. When measuring the blood ULBP2 levels in patients with other cancer types, including colorectal carcinoma, nasopharyngeal carcinoma and gastric cancer illustrates the blood ULBP2 levels are higher in patients with pancreatic cancer than other cancer types.

The invention provides a kit applied to nasopharynx cancer diagnosis, prognosis and treatment effect evaluation. The kit is that the expression level of EBV-miR-BART1-5p is detected to effectively reflect the condition of nasopharynx cancer so as to assist the diagnosis and treatment effect monitoring of nasopharynx cancer; in addition, the kit has potential application value in screening of high-risk population suffering from nasopharynx cancer. The kit further comprises a nasopharynx brush through which a sample of a diseased region of nasopharynx can be directly obtained; the nasopharynx brush has the advantages of being painless and free of invasiveness; in addition, cast-off cells obtained through the nasopharynx brush can directly reflect the feature of tumor in the nasopharynx; the sample obtained through the nasopharynx brush and the detection of the expression level of EBV-miR-BART1-5p help clinicians rapidly diagnose nasopharynx cancer; and in addition, the kit greatly assists the therapeutic effect monitor of nasopharynx cancer and follow-up visit.